Conclusion
LH can be an alternative to OH for primary HCC with favorably located
tumors due to the decreased intraoperative transfusion rate, shorter
postoperative hospital stay, and lower 90-day readmission rate. LH will
not compromise intraoperative blood loss, complication rate, morbidity,
90-day mortality rate, or long-term overall, and disease-free survival.
LH stabilize the short-term and long-term outcome for primary HCC
located at favorable location during the development period. Our
findings can provide the evidence and confidence for institutions who
want to start developing LH.